Literature DB >> 16244586

Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.

A Uner1, F A Ebinc, N Akyurek, D Unsal, B B Mentes, A Dursun.   

Abstract

AIM: To analyze vascular endothelial growth factor (VEGF), c-erbB-2 and c-erbB-3 expression and to evaluate their relation to clinicopathologic parameters and pathogenesis of colorectal carcinoma.
METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%). Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types. These differences were not statistically significant. The presence of distant metastasis and angiolymphatic invasion were identified as independent predictors of survival. A positive correlation was found between VEGF expression and lymphatic vessel invasion and regional lymph node involvement.
CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer. VEGF expression may be implicated in the lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244586

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  4 in total

Review 1.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

2.  Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas.

Authors:  Qingguo Li; Daorong Wang; Jing Li; Ping Chen
Journal:  BMC Cancer       Date:  2011-06-27       Impact factor: 4.430

3.  Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

Authors:  Erik J Blok; Peter Jk Kuppen; Jeroen Em van Leeuwen; Cornelis Fm Sier
Journal:  Clin Med Insights Oncol       Date:  2013-02-21

4.  Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array.

Authors:  Joon-Yong Chung; Till Braunschweig; Seung-Mo Hong; David S Kwon; Soo-Heang Eo; HyungJun Cho; Stephen M Hewitt
Journal:  Proteome Sci       Date:  2014-05-13       Impact factor: 2.480

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.